180 related articles for article (PubMed ID: 28204572)
1. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.
Heinzel A; Müller D; Yekta-Michael SS; Ceccon G; Langen KJ; Mottaghy FM; Wiesmann M; Kocher M; Hattingen E; Galldiks N
Neuro Oncol; 2017 Sep; 19(9):1271-1278. PubMed ID: 28204572
[TBL] [Abstract][Full Text] [Related]
2. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N
J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172
[TBL] [Abstract][Full Text] [Related]
3. Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy.
Ceccon G; Lohmann P; Stoffels G; Judov N; Filss CP; Rapp M; Bauer E; Hamisch C; Ruge MI; Kocher M; Kuchelmeister K; Sellhaus B; Sabel M; Fink GR; Shah NJ; Langen KJ; Galldiks N
Neuro Oncol; 2017 Feb; 19(2):281-288. PubMed ID: 27471107
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas.
Heinzel A; Stock S; Langen KJ; Müller D
Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1089-96. PubMed ID: 22419257
[TBL] [Abstract][Full Text] [Related]
5. MRI and
Rosen J; Werner JM; Ceccon GS; Rosen EK; Wollring MM; Stetter I; Lohmann P; Mottaghy FM; Fink GR; Langen KJ; Galldiks N
J Nucl Med; 2024 Jun; 65(6):838-844. PubMed ID: 38664020
[TBL] [Abstract][Full Text] [Related]
6. Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis.
Lohmann P; Kocher M; Ceccon G; Bauer EK; Stoffels G; Viswanathan S; Ruge MI; Neumaier B; Shah NJ; Fink GR; Langen KJ; Galldiks N
Neuroimage Clin; 2018; 20():537-542. PubMed ID: 30175040
[TBL] [Abstract][Full Text] [Related]
7. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis.
Galldiks N; Stoffels G; Filss CP; Piroth MD; Sabel M; Ruge MI; Herzog H; Shah NJ; Fink GR; Coenen HH; Langen KJ
J Nucl Med; 2012 Sep; 53(9):1367-74. PubMed ID: 22872742
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of
Rosen J; Ceccon G; Bauer EK; Werner JM; Tscherpel C; Dunkl V; Rapp M; Sabel M; Herrlinger U; Heinzel A; Schäfer N; Ruge M; Goldbrunner R; Stoffels G; Kabbasch C; Fink GR; Langen KJ; Galldiks N
J Nucl Med; 2022 Nov; 63(11):1677-1682. PubMed ID: 35422443
[TBL] [Abstract][Full Text] [Related]
9. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.
Pöpperl G; Götz C; Rachinger W; Gildehaus FJ; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1464-70. PubMed ID: 15248032
[TBL] [Abstract][Full Text] [Related]
10. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
11. Potential for differentiation of glioma recurrence from radionecrosis using integrated
Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
[TBL] [Abstract][Full Text] [Related]
12. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
[TBL] [Abstract][Full Text] [Related]
13. Suspected recurrence of brain metastases after focused high dose radiotherapy: can [
Romagna A; Unterrainer M; Schmid-Tannwald C; Brendel M; Tonn JC; Nachbichler SB; Muacevic A; Bartenstein P; Kreth FW; Albert NL
Radiat Oncol; 2016 Oct; 11(1):139. PubMed ID: 27769279
[TBL] [Abstract][Full Text] [Related]
14. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
[TBL] [Abstract][Full Text] [Related]
15. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas.
Rachinger W; Goetz C; Pöpperl G; Gildehaus FJ; Kreth FW; Holtmannspötter M; Herms J; Koch W; Tatsch K; Tonn JC
Neurosurgery; 2005 Sep; 57(3):505-11; discussion 505-11. PubMed ID: 16145529
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI.
Pyka T; Hiob D; Preibisch C; Gempt J; Wiestler B; Schlegel J; Straube C; Zimmer C
Eur J Radiol; 2018 Jun; 103():32-37. PubMed ID: 29803382
[TBL] [Abstract][Full Text] [Related]
19. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
[TBL] [Abstract][Full Text] [Related]
20. Can Early Postoperative O-(2-
Buchmann N; Gempt J; Ryang YM; Pyka T; Kirschke JS; Meyer B; Ringel F
World Neurosurg; 2019 Jan; 121():e467-e474. PubMed ID: 30267942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
